Sollis Therapeutics

About:

Sollis Therapeutics is a pharmaceutical company developing non-opioid analgesic solutions.

Top Investors: Deerfield, Neurotechnology Innovations Translator

Description:

Sollis Therapeutics is a clinical-stage specialty pharmaceutical company developing novel non-steroid, non-opioid analgesics. Sollis’ first product is an extended-release combination analgesic and anti-inflammatory drug designed for local delivery for the treatment of sciatica and other neuropathic pain syndromes. The company was founded in 2017 and is headquartered in Columbus, Ohio.

Total Funding Amount:

$52.5M

Estimated Revenue Range:

$1M to $10M

Headquarters Location:

Columbus, Ohio, United States

Founded Date:

2017-04-01

Founders:

Bryan Jones, Gregory Fiore

Number of Employees:

1-10

Last Funding Date:

2021-03-25

IPO Status:

Private

Industries: